Co-Founder and CEO
Receive the Tufts CSDD and Medable Research Paper
Medable partnered with Tufts CSDD, the leading independent research group on clinical development economics, to empirically answer the question: To what extent can clinical monitoring agents improve trial performance, and do those translate into measurable economic value for drug developers? Medable provided operational data – including operational time savings and agent cost – from its Clinical Monitoring Agent modeled in an oncology development program. Tufts CSDD applied the expected Net Present Value (eNPV) framework, a widely accepted method for quantifying the financial impact of innovation investments, to assess the value created by the AI agent.
The Tufts CSDD analysis specifically assessed the impact of Medable’s Clinical Monitoring Agent across three top-line metrics:
- Expected net present value
The agent showed eNPV gains of approximately $7.5 million (phase 2 trial), $11.3 million (combined phase 2 and phase 3) development, and $21 million (phase 3 trial). - Overall return on investment
The study found an estimated ROI of 64x for phase 2 and 82x for phase 3 trial. - Direct operating cost savings
Tufts CSDD estimated direct trial operating cost reductions of approximately $4.4 million per phase 2 and $5.6 million per phase 3 study.
A detailed paper will be published later this year. Sign-up to be the first to receive the final published paper.
Book a meeting
Schedule a meeting or demo with our platform experts at our DIA booth.
Sign up for the paper
Thank you
You are on the list. We will email you the full paper as soon as it is published.
Meet the Medable team
Come by booth #339 to talk with one of our clinical research and trial experts.
chief scientfic officer
Pamela Teanarts
Available to talk about the latest IRB and FDA recommendations.
EGM, Digital and Decentralized Solutions
Allison Holland
Discuss your DCT and enterprise solutions.
VP DCT Solutions
Musaddiq Khan
Medable’s expert on therapeutic area solutions.
Chief domain expert
Mohammed Ali
Disuss the creation and execution of strategic programs.
chief scientfic officer
Pamela Teanarts
Available to talk about the latest IRB and FDA recommendations.
EGM, Digital and Decentralized Solutions
Allison Holland
Discuss your DCT and enterprise solutions.
VP DCT Solutions
Musaddiq Khan
Medable’s expert on therapeutic area solutions.
Chief domain expert
Mohammed Ali
Disuss the creation and execution of strategic programs.
Innovation Theater: Driving the new era of clinical development
Join this session to see how leading pharma are using platforms to deliver digitally-enabled drug development transformation at scale. Explore the evolving regulatory guidance and latest research validating that decentralized approaches are here to stay.
Innovation Theater #3
Tuesday, June 27
12:30 PM EST
30 minutes
JUN
27
Innovation Theater: Driving the new era of clinical development
Join this session to see how leading pharma are using platforms to deliver digitally-enabled drug development transformation at scale. Explore the evolving regulatory guidance and latest research validating that decentralized approaches are here to stay.
- Innovation Theater #3
- Tuesday, June 27
- 12:30 PM EST
- 30 minutes
JUN
27
SESSION HIGHLIGHT
Responsibility and Oversight in Decentralized Clinical Trials
Join Medable’s CSO, Pamela Tenaerts to discuss issues that drive principal investigator (PI) oversight and responsibility in modern clinical trials where research and data gathering activities are no longer confined to the traditional site model.
Wed, June 28 | 10:30-11:30am
Wed, June 28 | 10:30-11:30am
ROUNDTABLE DISCUSSION
RWD: Maximizing Value and Quality through End-to-End Patient Centricity
Join Medable’s VP, Digital Transformation Strategy, Reem Yunis and Walgreen’s Head, Digital Optimization, RWE Clinical Trials, Kendal Whitlock for a follow up roundtable discussion tied to session: Real-World Data: Maximizing Value and Quality through End-to-End Patient Centricity.
Wed, June 28 | 1:15-2:15pm
Wed, June 28 | 1:15-2:15pm
You’re on the list.
Somebody will reach out to you soon to schedule a sneak peek of our upcoming product features and capabilities. In the meantime, enjoy our latest content about the future of clinical trials.
